In addition to inducing immunogenic cell death and type I IFN secretion, anthracyclines promote the recruitment of CCL2/CCR2–dependent functional antigen-presenting cells (APCs) into tumor sites but not into tumor-draining lymph nodes (Ma et al., 2014). Here, CCL2 is linked to neoplasm.